**Correction to: Arthritis Res Ther**

**https://doi.org/10.1186/s13075-019-1856-4**

Following publication of the original article \[[@CR1]\], the authors reported an error in Table [2](#Tab1){ref-type="table"}. The data for 'HAQ-DI response (MCID ≥ 0.3), n (%) / At week 52' for the 'Sarilumab 150 mg q2w + MTX' and 'Sarilumab 200 mg q2w + MTX' groups should be 41 (50.6) and 37 (46.3), respectively (last row, last two entries of the table).

The corrected table is given below.

Table 2Efficacy results (mITT population)SarilumabPlacebo to 150 mg q2w + MTX\
(*n* = 41 (*n* = 14 at week 52))^a^Placebo to 200 mg q2w + MTX\
(*n* = 40 (*n* = 15 at week 52))^a^150 mg q2w + MTX\
(*n* = 81)200 mg q2w + MTX\
(*n* = 80)Signs and symptoms ACR20 response, *n* (%)  At week 1215 (18.5)54 (66.7)^\*\*\*^52 (65.0)^\*\*\*^  At week 2412 (14.8)55 (67.9)^\*\*\*^46 (57.5)^\*\*\*^  At week 529 (64.3)10 (66.7)58 (71.6)48 (60.0) ACR50 response, *n* (%)  At week 125 (6.2)22 (27.2)^\*\*\*^25 (31.3)^\*\*\*^  At week 248 (9.9)35 (43.2)^\*\*\*^31 (38.8)^\*\*\*^  At week 528 (57.1)10 (66.7)37 (45.7)38 (47.5) ACR70 response, *n* (%)  At week 121 (1.2)5 (6.2)15 (18.8)^\*\*\*^  At week 243 (3.7)15 (18.5)^\*\*^12 (15.0)^\*^  At week 524 (28.6)3 (20.0)29 (35.8)22 (27.5) ACR components, mean (SD) change from baseline at week 24  Tender joint count− 9.1 (10.2)− 13.4 (9.9)− 12.4 (11.3)  Swollen joint count− 7.2 (6.7)− 10.6 (8.1)− 9.5 (9.1)  Pain VAS− 22.9 (27.7)− 36.5 (23.4)− 30.2 (23.3)  Physician global VAS− 26.8 (18.4)− 41.8 (21.6)− 43.9 (19.4)  Patient global VAS− 18.3 (22.6)− 32.4 (21.0)− 30.6 (21.9)  HAQ-DI− 0.3 (0.4)− 0.5 (0.5)− 0.6 (0.5)  CRP, mg/l− 1.7 (12.2)− 21.1 (19.5)− 21.3 (18.0) DAS28-CRP response, mean (SD) change from baseline  At week 12− 0.8 (1.1)− 2.3 (1.1)^\*\*\*^− 2.3 (1.2)^\*\*\*^  At week 24− 1.5 (1.2)− 2.8 (1.0)^\*\*\*^− 2.8 (1.1)^\*\*\*^  At week 52− 3.1 (1.2)− 2.9 (1.2)− 3.2 (1.2)− 3.2 (1.1) DAS28-CRP \< 2.6, *n* (%)  At week 123 (3.7)21 (25.9)^\*\*\*^27 (33.8)^\*\*\*^  At week 246 (7.4)29 (35.8)^\*\*\*^32 (40.0)^\*\*\*^  At week 527 (50.0)9 (60.0)41 (50.6)43 (53.8) SDAI, mean (SD) change from baseline  At week 12− 8.9 (12.0)− 20.7 (11.0)^\*\*\*^− 18.9 (11.6)^\*\*\*^  At week 24− 16.0 (11.6)− 25.2 (11.6)^\*\*\*^− 23.8 (11.3)^\*\*\*^  At week 52− 29.6 (9.9)− 23.4 (12.4)− 29.4 (13.6)− 26.9 (11.5) SDAI ≤ 3.3, *n* (%)  At week 1202 (2.5)7 (8.8)^\*\*^  At week 241 (1.2)5 (6.2)10 (12.5)^\*\*^  At week 522 (14.3)1 (6.7)19 (23.5)18 (22.5) CDAI, mean (SD) change from baseline  At week 12− 8.7 (11.4)− 18.8 (10.6)^\*\*\*^− 16.8 (10.9)^\*\*\*^  At week 24− 15.7 (11.1)− 23.1 (11.2)^\*\*\*^− 21.7 (10.7)^\*\*\*^  At week 52− 28.4 (9.7)− 21.1 (11.4)− 27.2 (13.1)− 24.8 (10.8) CDAI ≤ 2.8, *n* (%)  At week 1201 (1.2)5 (6.3)^\*^  At week 241 (1.2)5 (6.2)8 (10.0)^\*^  At week 521 (7.1)017 (21.0)15 (18.8)Physical function HAQ-DI, mean (SD) change from baseline  At week 12− 0.1 (0.3)− 0.4 (0.5)^\*\*\*^− 0.4 (0.5)^\*\*\*^  At week 24− 0.3 (0.4)− 0.5 (0.5)^\*\*\*^− 0.6 (0.5)^\*\*\*^  At week 52− 0.7 (0.6)− 0.5 (0.3)− 0.6 (0.6)− 0.6 (0.6) HAQ-DI response (MCID ≥ 0.3), *n* (%)  At week 1219 (23.5)39 (48.1)^\*\*^38 (47.5)^\*\*^  At week 1619 (23.5)37 (45.7)^\*\*^37 (46.3)^\*\*^  At week 2410 (12.3)39 (48.1)^\*\*\*^39 (48.8)^\*\*\*^  At week 529 (64.3)8 (53.3)41 (50.6)37 (46.3)\**p* \<  0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001^*a*^Data for combined placebo groups (*n*=81) shown at weeks 12, 16 and 24. ACR American College of Rheumatology, *ACR20/50/70* American College of Rheumatology 20%/50%/70% improvement criteria, *CDAI* Clinical Disease Activity Index, *CRP* C-reactive protein, *DAS28* Disease Activity Score 28-joint count, *HAQ-DI* Health Assessment Questionnaire-Disability Index, *MCID* minimum clinically important difference, *mITT* modified intent-to-treat, *MTX* methotrexate, *q2w* every 2 weeks, *SDAI* Simplified Disease Activity Index, *SD* standard deviation, *SJC* swollen joint count, *TJC* tender joint count, *VAS* visual analog scale
